Home » Newsletters » BioWorld Science

BioWorld Science

July 23, 2010

View Archived Issues

Phase IIa data disclosed on tideglusib in Alzheimer's disease

Novartis reviews second quarter of 2010

EVP-0015962 improves cognitive deficit in mouse model of Alzheimer's disease

PDIP-38 is a candidate biomarker for progression of HPV-16-associated cervical dysplasia

Insulin degludec improves glucemic control in phase II trials in type 1 and 2 diabetes

Drug-targetable rearrangements of RAF kinase pathway members identified in prostate cancer

Repros Therapeutics to start low-dose study of Proellex

Tarsa advances phase III oral calcitonin trial in postmenopausal osteoporosis

Enrollment begins in phase II MM-121 trial in breast cancer

NACI updates recommendations on rotavirus vaccination in Canada

University of Michigan claims new STAT-3 inhibitors

AiCuris discloses new anti-HIV agents

Algeta concludes manufacture and supply agreements for alpharadin

S/GSK-1265744 is active against RAL-resistant HIV isolates in vitro

Fresenius Medical Care expands its dialysis products business

FDA grants CBLB-502 fast track status for acute radiation syndrome

DSMB recommends completion of phase II FV-100 trial in shingles

NPS Pharma advances phase III trial of teduglutide in short bowel syndrome

ConjuChem Biotechnologies files for bankruptcy

CP-404 successfully completes pilot phase I study for obesity

CHMP concludes topical ketoprofen has positive benefit-to-risk balance

Euthymics Bioscience acquires DOV Pharma and continues EB-1010 development

MDRNA shareholders approve Cequent acquisition and name change to Marina Biotech

Korean scientists discover new cyclic penta-depsipeptides

Sirtris Pharmaceuticals describes new SIRT modulators

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...